We have previously posted about Merck's questionable marketing strategies for the promotion of Vioxx (here), how it attempted to discredit reports of Vioxx's adverse effects (here), how it oversold Vioxx as a first-line analgesic, thus exposing more patients to its risks (here), and most recently, how the published report of a key trial of Vioxx was ghost-written (here). Thus, Gilmartin's resignation seems the honorable thing to do.
The question is now whether Clark, who evidently has no clinical or scientific experience, will be able to restore Merck's once pristine ethical reputation. We hope he does.
0 Response to "Merck CEO Quits"
Post a Comment
Thank you for visitting on Medical Insurance - Health insurance, health care, and medical insurance coverage. Left your comment in comment-box below.